A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 13, 2019

Primary Completion Date

February 3, 2025

Study Completion Date

February 3, 2025

Conditions

Head and Neck Cancer

Interventions

BIOLOGICAL

PepCan

50 μg peptide + 0.3mL Candin® per dose administered intradermally in the extremities

BIOLOGICAL

Placebo

0.9% Saline solution per dose administered intradermally in the extremities

Trial Locations (1)

University of Arkansas for Medical Sciences, Little Rock

All Listed Sponsors

lead

University of Arkansas

OTHER

NCT03821272 - A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients | Biotech Hunter | Biotech Hunter